Cyn3rgy Research is conducting a Phase 4, randomized, double-blind, multicenter, placebo-controlled, parallel-group study of the efficacy and safety od SPN-812 in preschool-age children (4 to 5 years old) with Attention-Deficit/Hyperactivity Disorder (ADHD). 

Qualified participants will be compensated for time and travel.